SecBot SecBot

Maintaining Investments in New Innovation Act

H.R. 1672 Rep. Donald Davis (D-NC-1) In committee
Bill text PDF
  1. Introduced Feb 27
  2. Committee Feb 27
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Feb 27, 2025Next: House vote
608d ago Feb 27, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
6companies, 104 filings
Subscribe to see spend
Member trades
14trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

6 companies
Companies by sector
Biotech & Pharma 6
Search all 6 companies, their asks and price moves Subscribe

Summary

Maintaining Investments in New Innovation Act

Full summary1 paragraphs

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Library of Congress summary, Feb 27, 2025

Summary versions
  • Introduced in HouseFeb 27, 2025

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.